INKT - MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference
NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 27 th , 2022, at 12:00 pm ET.
Access to the live presentation is available at https://www.webcaster4.com/Webcast/Page/2828/44096
A replay will be available after the call on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/ .
Contact
MiNK Therapeutics
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com